Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3
Open Access
- 22 March 2001
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 67 (1) , 51-53
- https://doi.org/10.1002/ajh.1076
Abstract
Eight of 35 patients with cancer receiving COL‐3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51–53, 2001. Published 2001 Wiley‐Liss, Inc.Keywords
This publication has 11 references indexed in Scilit:
- Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic CancerJournal of Clinical Oncology, 2001
- Minocycline‐induced hemolytic anemiaPediatrics International, 1994
- Hemolytic Anemia after Tetracycline TherapyNew England Journal of Medicine, 1985
- Tetracycline-induced hemolytic anemiaJournal of the American Academy of Dermatology, 1980
- Tetracycline-Induced Aplastic AnemiaSouthern Medical Journal, 1979
- Tetracycline‐Induced Immune Hemolytic AnemiaTransfusion, 1974
- Megaloblastic Anemia Associated with Long-Term Tetracycline TherapyAnnals of Internal Medicine, 1973
- Antituberculous Drugs and Sideroblastic AnaemiaBritish Journal of Haematology, 1965
- Sideroblastic Anaemia in Man: Observations on Seventy CasesBritish Journal of Haematology, 1965
- Abnormal ("Ringed") Sideroblasts in Various Hematologic and Non-Hematologic DisordersBlood, 1961